Similar articles

• Case records of the Massachusetts General Hospital. Case 31-2011. A 55-year-old man with oligometastatic lung cancer.

  Lanuti M, Sequist LV, Sharma A, Mino-Kenudson M. Lanuti M, et al. N Engl J Med. 2011 Oct 13;365(15):1426-35. doi: 10.1056/NEJMcpc1013930. N Engl J Med. 2011. PMID: 21995391 No abstract available.
• Efficacy of gefitinib in a patient with lung cancer associated with idiopathic pulmonary fibrosis.

  Kishi K, Nakata K, Yoshimura K. Kishi K, et al. J Thorac Oncol. 2006 Sep;1(7):733-4. J Thorac Oncol. 2006. PMID: 17409949 No abstract available.
• Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure.

  Gridelli C, Maione P, Galetta D, Rossi A. Gridelli C, et al. J Thorac Oncol. 2007 Jan;2(1):96-8. doi: 10.1097/JTO.0b013e31802bffb0. J Thorac Oncol. 2007. PMID: 17410020 No abstract available.
• Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva , OSI-774), in the treatment of bronchioloalveolar carcinoma.

  DeGrendele H. DeGrendele H. Clin Lung Cancer. 2003 Sep;5(2):83-5. doi: 10.1016/S1525-7304(11)70324-2. Clin Lung Cancer. 2003. PMID: 14596689 Review. No abstract available.
• Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.

  Reddy GK. Reddy GK. Clin Lung Cancer. 2005 Nov;7(3):163-5. doi: 10.1016/S1525-7304(11)70404-1. Clin Lung Cancer. 2005. PMID: 16354309 Review. No abstract available.